Clearmind Medicine Inc (CMND) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jan 31 2026 to 0 - CSIMarket
Clearmind Medicine Inc's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Clearmind Medicine Inc's ROA in the first quarter of 2026?
Clearmind Medicine Inc recorded a cumulative net loss of $-12 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -217.11%.
However, within the Healthcare sector 701 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2025 from to 4457.
Pioneering Psychedelic Frontiers: Clearmind Medicine s Strategic Leap in Alcohol Use Disorder Treatment Trials Clearmind Medicine Inc. has taken significant strides toward transforming the landscape of alcohol use disorder (AUD) treatment by embracing psychedelic-derived therapeutics. The company, listed on various exchanges including Nasdaq and CSE (under the symbol CMND), and FSE (under the symbol CWY), has recently garnered approval from multiple regulatory bodies, marking key milestones in its pioneering clinical trial ventures. Regulatory Triumphs and Strategic Advancement: In March 2024, Clearmind Medicine successfully obtained approval from the Israeli Ministry of Health to initiate its phase I/IIa clinical trial using the proprietary MEAI-based CMND-100 oral capsule designed for AUD patients. This approval follows swiftly on the heels of prior clearance from the United States Food and Drug Administration (FDA), empowering Clearmind to conduct its groundbreaking human clinical trials at an additional site. The FDA s approval of the Investigational New Drug (IND) submission underscores the safety and promising potential of the psychedelic compound CMND-100.
Vancouver, Canada, August 29, 2024 In an era of scientific advancement and relentless pursuit of innovative solutions for hitherto inadequately addressed health maladies, Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) hereafter referred to as Clearmind or the Company emerges as a torchbearer of pioneering biotechnology. The distinguished clinical-stage enterprise has announced the publication of its patent application under the auspices of the international Patent Cooperation Treaty (PCT), signifying a milestone in its ambitious endeavour to explore novel psychedelic-derived therapeutics.The patent, which propounds an avant-garde combination of Ketamine and N-Acylethanolamines, epitomizes Clearmind s dedication to innovating within the intersection of neuropharmacology and integrative medicine. This synergistic amalgamation holds the potential to revolutionise therapeutic paradigms, particularly for conditions that have persistently eluded effective treatment.
Clearmind Medicine Secures U.S. Patent for Binge Behavior Treatment Amid Financial Challenges Vancouver, Canada August 21, 2024 Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0), a clinical-stage biotech company pioneering psychedelic-derived therapeutics, has reached a significant milestone by securing a new patent approval from the United States Patent and Trademark Office. This patent is a critical addition to the company s MEAI-based binge behavior regulator program, positioning Clearmind at the forefront of tackling major under-treated health issues. A Major Milestone in Psychedelic-Derived TherapiesClearmind Medicine’s innovative approach targets the root of binge behaviors, aiming to provide a groundbreaking solution in the realm of mental health and addiction treatments. Their new patent approval underscores a substantial advancement for the company, fortifying its intellectual property portfolio. It also demonstrates the potential of MEAI-based therapies, which seek to regulate and moderate binge behaviors, addressing a global public health concern.
In a world grappling with a mental health crisis, innovative solutions are desperately needed. The psychedelic renaissance is upon us, and companies like Clearmind Medicine Inc. (Nasdaq: CMND) are leading the way in developing novel therapies designed to tackle under-treated and often debilitating health conditions. Recently, Clearmind has made significant strides by expanding its collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem, focusing on advanced psychedelic compounds that promise to change the landscape of mental health treatment. The Collaboration: Pioneering New HeightsOn August 16, 2024, Clearmind Medicine announced the submission of a patent application under the International Patent Cooperation Treaty (PCT). This application is a critical step in their collaboration with Yissum, where Clearmind has secured exclusive licensing rights to innovative psychedelic derivatives. This partnership is not just about securing patents; it s about ushering in a new era of mental health therapeutics. The collaboration taps into groundbreaking research led by esteemed professors from the Hebrew University, including Rami Yaka, Ahmed Masaewa, and Avi Priel, who are at the forefront of psychedelic science.
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0), a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics, has recently made significant advancements in its mission to transform the healthcare sector. The company s latest agreement to source manufacturers and distributors for its alcohol substitute beverage product marks a crucial milestone in revolutionizing alcohol consumption.Vancouver-based Clearmind Medicine is at the forefront of leveraging psychedelic therapies for the treatment of various mental health conditions and substance abuse disorders. With a mission to explore alternative treatment options, the company has now set its sights on transforming the way society approaches alcohol consumption.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
